Compare Honeywell International Inc (HON) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Honeywell International Inc trades at $231.56 (market cap $72.93B), while Regeneron Pharmaceuticals Inc trades at $794.94 (market cap $82.06B). The key difference: Honeywell International Inc and Regeneron Pharmaceuticals Inc are close in size by market cap, and Honeywell International Inc pays the higher dividend (1.22%). Which is the better fit depends on your goals.
| HON | REGN | |
|---|---|---|
Market Cap | $72.93B | $82.06B |
Sector | Industrials | Health |
52-Week High | $248.79 | $812.27 |
52-Week Low | $188.14 | $555.51 |
Enterprise Value | $97.73B | $76.77B |
Dividend Yield | 1.22% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $242.93, down 1.32% on the day, with a bullish technical signal and strong fundamentals including a P/E of 8.85 and net income margin of 21.58%. Recent corporate actions include a 2:1 reverse stock split and consistent dividend payments. The stock shows robust earnings beats in recent quarters, though Q3 2026 results are pending.
The outlook is positive with a consensus price target of $320.54, indicating significant upside. Risks include recent growth guidance disappointments and competitive pressures in industrial automation. Analyst sentiment is predominantly buy-rated, supporting a favorable investment case amid ongoing portfolio simplification.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
